Phil Tsai is the Chief Technical Officer at Immunone, responsible for delivering high-quality targeted therapy to cancer patients. Before Immunone, Phil worked at Seagen for 21 years and held various positions of increasing responsibilities. Most recently, he was the Senior Vice President of Technical Development from June 2021 until December 2023 and, after the Pfizer acquisition, from December 2023 until April 2024. During his tenure at Seagen, he was responsible for accelerating Seagen’s pipeline molecules from discovery to clinical development and commercialization.
Phil oversaw end-to-end development of biologics and small molecule drug-linker manufacturing processes, analytics, and drug products. He has built and led a highly productive organization with expanding capabilities over two decades from a group of 10 to 300+ staff with an annual budget of $150+ million, supporting a pipeline of 30 molecules. Phil possesses deep expertise in ADC development and a proven track record of gaining global regulatory acceptance of CMC strategies. He helped establish the industry’s first antibody-drug conjugate (ADC) manufacturing platform. He guided the manufacturing control strategy development for the successful approval of all of Seagen’s marketed products, including the industry’s first breakthrough ADC product, Adcetris®.
- Primary/Complementary Interactive Styles: Warrior and Expert/Romantic (equal secondary styles)
- Interactive Combination: The Sage and Hired Gun
- In a film, he’d be played by: Daniel Craig
- Common Leadership Characteristic: Driven to get results by employing a logical strategy, detailed knowledge, and through selling ideas
